Overview

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban versus fondaparinux in the treatment of superficial vein thrombosis (SVT).
Phase:
Phase 3
Details
Lead Sponsor:
GWT-TUD GmbH
Collaborator:
Bayer
Treatments:
Fondaparinux
PENTA
Rivaroxaban